-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$39.71209.03% Upside
Pliant Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Pliant Therapeutics, Inc.?
Pliant Therapeutics, Inc. has been rated by research analysts at H.C. Wainwright, Leerink Partners, Piper Sandler, Stifel Nicolaus, Oppenheimer, RBC Capital in the past 90 days.